- authorisedTherapeutic confirmatory (Phase III)
A multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of a subcutaneous allergoid preparation of house dust mite allergens (Dermatophagoides pteronyssinus / Dermatophagoides farinae) in patients with moderate to severe allergic rhinitis/rhinoconjunctivitis with or without controlled allergic asthma.
This study tests a new allergy injection for adults with moderate to severe house dust mite allergies. Researchers want to see if regular injections can train the immune system to reduce symptoms like sneezing, runny noses, and itchy eyes, while lowering the need for daily allergy medicines over one year.
Spain - active not recruitingPHASE3
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
This study is testing a new injection treatment for house dust mite allergy. It aims to see if it reduces allergy symptoms and is safe for adults with moderate to severe allergic rhinitis, with or without asthma. The treatment is given over one year.
Bulgaria · Germany · Latvia